The RNA-binding protein, UPF1, is best known for its central role in the nonsense-mediated RNA decay (NMD) pathway. Feng et al. now report a new function for UPF1-it is an E3 ubiquitin ligase that specifically promotes the decay of a key pro-muscle transcription factor: MYOD. UPF1 achieves this through its RING-like domain, which confers ubiquitin E3 ligase activity. Feng et al. provide evidence that the ability of UPF1 to destabilize MYOD represses myogenesis. In the future, it will be important to define other protein substrates of UPF1-driven ubiquitination and to determine whether this biochemical activity is responsible for some of UPF1's previously defined biological functions, including in development and stress responses. 
Introduction
NMD is a RNA turnover pathway originally discovered by virtue of its ability to degrade aberrant RNAs harboring premature termination codons (PTCs). In this role, NMD serves as a quality control pathway that protects cells from the potential deleterious effects of the truncated protein products arising from PTCcontaining mRNAs. [1] [2] [3] More recently, NMD has been shown to selectively degrade a subset of normal mRNAs in species spanning the phylogenetic scale. [1, 4] This finding, coupled with the fact that NMD activity varies between cell types, tissues, and developmental stages, [5] has lead to a model in which shifts in NMD magnitude lead to alterations in the transcriptome to achieve specific biological outcomes. For example, NMD is regarded as being important for a wide variety of developmental events, based on the developmental defects that occur as a result of loss or knockdown of NMD factors in a variety of species. [6] While most studies have focused on how loss of RNA decay might contribute to these defects, it is also possible that auxiliary roles of NMD factors could instead be responsible, a theme we touch on later in this commentary.
Arguably the most critical protein in the NMD pathway is UPF1, a RNA helicase involved in nearly every step of the NMD process, from target discrimination, [7] to remodeling the NMD-mRNA complex and enhancing nuclease access to the mRNA. [8] UPF1 is thought to mediate the degradation of NMD substrates through a phosphorylation/dephosphorylation cycle. While the precise role of this cycle remains unclear, evidence suggests that phosphorylation of UPF1 is critical for NMD, while dephosphorylation allows for UPF1 recycling. [9] UPF1 has been ascribed many biological roles. For example, UPF1 is thought to be critical for early embryonic development in mammals, based on the finding that Upf1-null mice suffer from early embryonic lethality. [10] Loss of UPF1 also causes embryonic lethality in zebrafish and flies, [11, 12] but has only minimal impact on simpler organisms such as Caenorhabditis elegans and Saccharomyces cerevisiae.
[6] UPF1's underlying mechanism of action in development is largely unknown. However, there has been some recent insight into this issue. For example, UPF1 has been shown to support the development of fly embryos by degrading GADD45B mRNA. [13] In mammals, UPF1 promotes the neural stem cell state and must be downregulated to drive neural differentiation, as this allows the mRNA encoding the pro-neural factor, SMAD7, to be stabilized. [14, 15] Relevant to the topic of this commentary, UPF1 is also downregulated during the process of myogenesis, [16] suggesting that this downregulatory response accelerates and possibly amplifies the generation of muscle cells during myogenesis.
While it is often assumed that these biological activities of UPF1 derive from its well-established role in NMD, UPF1 also functions in other pathways. For example, it participates in the histone mRNA decay and staufen (STAU)1-mediated RNA decay (SMD) pathways. [9] In histone RNA decay, stem-loopbinding protein (SLBP) binds to a conserved stem-loop structure found in the 3 0 end of histone mRNAs and recruits UPF1 to trigger mRNA decay. [9] In SMD, mRNAs containing a STAU1-binding site downstream of a termination codon in the 3 0 UTR are bound by STAU1 and UPF1, resulting in UPF1 phosphorylation and RNA decay. [9] There is also evidence that UPF1 functions in genome maintenance, including in DNA replication, DNA damage responses, [17] and telomere replication. [17, 18] A common thread in all these roles is nucleic acid, which is consistent with UPF1's biochemical function as an RNA/DNA helicase. It is also consistent with the fact that UPF1's various functions are perturbed by mutations in the region of UPF1 encodings its helicase domain ( Figure 1 and references therein).
Given all these functions for UPF1, one might surmise that the surprises are over. Writing recently in Molecular Cell, Feng et al. [19] report a new function for human UPF1 -it promotes protein decay. They show that human UPF1 is a E3 ubiquitin ligase and that it directly mediates protein decay. They provide a biological link for this new function by showing that human UPF1 represses myogenesis through its activity as an E3 ubiquitin ligase and that it promotes the decay of the myogenesis-promoting transcription factor MYOD.
2. Discovery That Human UPF1 Is an E3 Ubiquitin Ligase
UPF1 Represses Myogenesis
To determine whether UPF1 has a causal role in myogenesis, Feng et al. performed UPF1 knockdown and overexpression experiments. They found that UPF1 knockdown accelerated the differentiation of the immortalized human myoblast cell lines 54-1 and MB135. They observed a similar effect of UPF1 knockdown in two primary human skeletal myoblast cell cultures. Conversely, UPF1 overexpression slowed myogenesis. Together, this data provided strong evidence that UPF1 represses human myogenesis, at least in vitro.
What physiological role might this myogenic-inhibitory activity have? A clue is previous work showing that UPF1 levels and NMD efficiency are decreased when mouse myoblasts undergo differentiation in vitro. [16] This previous discovery, coupled with the findings of Feng et al., support a model in which reduced UPF1 levels allow for myogenesis to proceed ( Figure 2 ).
UPF1 Targets the Myogenic Transcription Factor, MYOD, for Protein Decay
One mechanism by which UPF1 could inhibit myogenesis is by degrading the mRNA encoding the pro-myogenic transcription factor, MYOGENIN (MYOG), as this RNA was previously shown to be a NMD target. [16] However, Feng et al. found that MYOG mRNA level did not increase in response to UPF1 knockdown until 2 days after induction of differentiation, which made it a poor candidate to dictate the modulatory effects of UPF1 on differentiation.
To obtain a perspective on the range of RNAs regulated by UPF1 in human myoblasts, the authors turned to RNAseq analysis. This analysis revealed that a relatively large number of genes dysregulated in response to UPF1 knockdown are targets of a master myogeneic transcription factor in the same subfamily as MYOG, called MYOD. This result suggested that UPF1 modulates the MYOD transcriptional program. It also raised the possibility that MYOD is a key target of NMD responsible for the ability of UPF1 to repress myogenesis. In support of MYOD mRNA being a direct NMD target transcript, the steady-state level of MYOD mRNA increased in response to UPF1 knockdown. However, MYOD mRNA stability was not increased by UPF1 knockdown, as would have been expected if it were a direct target. Pre-mRNA analysis revealed that the increase in MYOD steady state mRNA levels in response to UPF1 knockdown likely resulted from increased transcription, rather than inhibited RNA decay. This finding illustrates the challenges of defining NMD target mRNAs, as mere upregulation of an mRNA in response to NMD perturbation is clearly not sufficient to define a direct target of the NMD pathway.
These results implied that UPF1 somehow decreases MYOD protein level by a means other than destabilizing MYOD RNA. In further support, the authors found that UPF1 knockdown increased MYOD protein level before a measurable increase in MYOD steady-state mRNA level. These surprising results motivated Feng et al. to determine whether instead UPF1 destabilizes MYOD protein. To test this, they made use of the protease inhibitor MG132 and found that it perturbed UPF1's ability to decrease MYOD protein level, consistent with the possibility that UPF1 promotes the destabilization of MYOD protein.
A traditional model would be that UPF1 achieves this indirectly by degrading a mRNA encoding a protein involved in the stabilization of MYOD protein. However, several lines of previously published evidence suggested that UPF1 might directly act to destabilize MYOD. For example, proteomic studies had shown that UPF1 interacts with several components of the ubiquitination and proteasome machinery. [20, 21] Furthermore, UPF1 itself contains an N-terminal cysteine-and histidine-rich domain that is structurally similar to the RING domain found in one of the two major types of eukaryotic E3 ubiquitin ligases. [22] Indeed, a previous study had found that S. cerevisiae Upf1 uses this domain to undergo selfubiquitination. [23] This study also showed that 1) this RING-like domain is conserved from yeast to humans, 2) the domain interacts with a yeast E2 conjugase, Ubc3, and 3) Figure 1 . Domain structure of human UPF1 with its various molecular functions highlighted. Domain structure adapted from Dehghani-Tafti and Sanders. [38] The CH domain is involved in binding several factors (highlighted below the bold line). It is not currently known whether this domain binds SLBP, but seems likely given the similarities between SMD and histone mRNA decay. [9] The RING domain reported by Feng et al. [19] is contained within the CH domain (highlighted by the red line). Mutations within the RING domain disrupt UPF1's ubiquitination and protein degradation activity. [19] Mutations that disrupt the RNA helicase activity of UPF1 perturb UPF1's function in NMD, [39] SMD, [40] telomere replication, [41] and histone mRNA decay. [37] It has not been directly tested whether the helicase domain is required for UPF1's putative function in DNA replication, but seems likely given that it is a nucleic acid-dependent process. The SQ domain contains numerous serine residues that are phosphorylated by SMG1 to drive UPF1 function. [23] Armed with this knowledge, the authors then tested whether human UPF1 might ubiquitinate MYOD. They made three observations supporting this possibility. First, MYOD ubiquitination was reduced in cells expressing the UPF1 RING domain mutant. Second, MYOD and UPF1 physically interacted in a manner that was stabilized by disrupting UPF1's RING domain. Third, ubiquitin associated with the UPF1 RING domain mutant, but not with WT UPF1, suggesting that the mutant failed to transfer ubiquitin to its substrate. This mutant did not appear to impact the ability of UPF1 to function in NMD, based on the finding that the levels of a few endogenous NMD substrates were not affected by expression of the mutant. This preliminary finding suggested that the mutant could be used to distinguish between UPF1's effects on NMD and ubiquitination.
To determine whether UPF1 destabilizes MYOD protein in muscle cells, the authors induced UPF1 expression from a tetracycline-regulated expression vector in stably transfected myoblast cells. They found that this led to rapid degradation of MYOD protein, as measured by half-life analysis. Degradation of the MYOD protein depended on UPF1's RING domain, as expression of the UPF1 RING domain mutant did not trigger MYOD protein degradation. Together, these data provided compelling evidence that human UPF1 uses its E3 ligase activity to degrade MYOD protein.
Evidence That UPF1 Represses Myogenesis Through Its RING Domain
To assess the physiological significance of UPF1's RING domain, Feng et al. compared the ability of myoblasts to undergo differentiation in response to wild-type UPF1 versus RINGmutant UPF1. They found that in contrast to wild-type UPF1, which slowed myogenesis, mutant UPF1 accelerated myogenesis, as shown by a rapid (albeit modest) increase in myogeneic Figure 2 . Model for UPF1's role in myogenesis. A) Diagram depicting UPF1, MYOD, and MYOG protein levels as myoblasts differentiate into myotubes. B) (Left panel) In myoblasts, UPF1 levels are high, allowing UPF1 to degrade the myogenic MYOG mRNA [16] through UPF1's NMD activity, and to degrade the myogenic MYOD protein through UPF1's E3 ubiquitin ligase activity. [19] UPF1's negative effect on MYOD protein and MYOG mRNA levels correlates with the low levels of these factors in myoblasts. (Right panel) When myoblasts differentiate into myotubes, UPF1 levels drop, which may allow MYOG mRNA and MYOD protein to escape degradation, correlating with the high levels of these factors in differentiated muscle cells (myotubes). The fact that human UPF1 can act as an E3 ubiquitin ligase and thereby promote protein degradation, indicates that UPF1 can directly shape more than just the transcriptome. An important future research direction will be to identify the full gamut of proteins directly ubiquitinated by UPF1. A recent proteome-wide analysis of proteins with altered abundance upon UPF1 depletion could be used as a starting point for identifying proteins that are destabilized by UPF1. [24] A major challenge in defining the extent of UPF1's ability to shape the proteome will be dissociating UPF1's RNA degradation activity from its ubiquitination/protein degradation activity, as both processes ultimately dictate protein level. In this regard, the UPF1 RING-domain mutant identified by Feng et al. that lacks E3 ligase activity and appears to have normal NMD activity could be used as a tool to distinguish whether UPF1 acts upon a given protein through its role in protein decay versus RNA decay (or a combination of the two).
Another potential substrate of human UPF1's E3 ligase activity is UPF1 itself, based on the finding that yeast Upf1 selfubiquitinates in vitro. [23] This self-ubiquitination might serve as a homeostatic mechanism to buffer UPF1 levels, or it may act to regulate UPF1's activity in response to external stimuli.
Another important future goal is to determine how UPF1 identifies its substrates for ubiquitination. Are there specific features in the proteins that UPF1 recognizes, or does ubiquitination occur simply through proximity?
How, Why, and To What Extent Does UPF1 Modulate Myogenesis?
How does UPF1 repress myogenesis? The authors favor the notion that UPF1 inhibits myogenesis through UPF1's ability to destabilize MYOD protein. This notion is particularly compelling given that MYOD is a powerful and well-established promyogenic transcription factor. [25] However, it is also possible that UPF1 inhibits myogenesis through decay of some factor other than (or in addition to) MYOD. To address this question, it will be important to perform rescue experiments with MYOD and other potential downstream targets.
The physiological relevance of UPF1's modulatory role in myogenesis also remains to be determined. One possibility is that it is part of a feedback network to control muscle mass. Various stressors are known to inhibit NMD, probably as a means to regulate biological responses. [26] If exercise stress also inhibits NMD, this would be predicted to amplify myogenesis as a means to build muscle mass.
Currently the evidence in favor of UPF1 functioning in myogenesis is derived from in vitro cell models of myogenesis. [16, 19] Is this also the case in vivo? To address this question in mice, it will be necessary to conditionally ablate Upf1 in myogenic cells, as global Upf1 knockout is embryonic lethal. [10] 3.3 What Is the Relationship Between mRNA and Protein Decay?
The discovery that UPF1 can act directly to initiate protein degradation raises the question as to whether this activity is coupled to UPF1's RNA decay-promoting activity. Feng et al. showed that MYOD protein is destabilized by UPF1, while MYOD mRNA is not destabilized by UPF1, suggesting that-in human cells-the two processes are not coupled, at least in this instance. This hypothesis is also supported by the finding that disruption of the RING domain of human UPF1 appears not to compromise its NMD activity. However, studies in S. cerevisiae suggest that the two activities can be coupled. One line of evidence for this is the finding that mutations in the yeast UPF1 RING domain disrupt NMD, [23] which is consistent with the fact that this region of UPF1 is required for binding UPF2. [22] Another line of evidence is studies demonstrating UPF1-dependent decay of peptides translated from PTC-containing transcripts in yeast. [27, 28] It remains to be determined whether the mechanism responsible for this UPF1-dependent peptide decay is the E3 ligase activity of Upf1.
If indeed it is found that a coupled RNA and protein decay system exists, such a system could be used to dramatically up-or down-regulate proteins to achieve physiological goals. For example, a coupled RNA and protein decay system would allow for efficient quality control; that is, strong downregulation of mutant proteins from aberrant genes harboring PTCs. By both increasing the rate of RNA and protein decay, UPF1 could largely eliminate mutant proteins, thereby avoiding potential dominantnegative effects.
Alternatively, no dedicated coupled RNA and protein decay system may exist. Instead, there may have been selection pressure over evolutionary time for UPF1 to take a multi-prong approach to achieve a given physiological goal. For example, UPF1 may dampen myogenesis by not only destabilizing MYOD protein but also by degrading mRNAs encoding other promyogenic components. This hypothesis is consistent with the finding that MYOG mRNA is a NMD target mRNA (Figure 2) . [16] It will be intriguing to test this "multi-prong" function hypothesis by performing rescue experiments with candidate UPF1 RNA and protein targets.
What Is the Biological Importance of UPF1's Protein Decay Activity?
In the future, it will be critical to determine whether other biological functions ascribed to UPF1 come from its protein degradation activity. Examples of known roles of UPF1 include: 1) it promotes neural stemness, [14, 29] 2) it appears to act as a tumor suppressor in cell lines, [30] and 3) it binds to members of the large long intersperse element-1 (LINE1) family and modulates both LINE1 expression and transposition. [31] Loss of UPF1's ubiquitination activity could also contribute to a number of diseases associated with loss or reduction of UPF1, including cancer [32, 33] and facio-scapulohumeral muscular dystrophy. [34] In addition, UPF1's roles outside of NMD (Figure 1 ) may involve its protein degradation function. For instance, it is tempting to speculate that UPF1's function in histone metabolism might not only be through its ability to directly target histone mRNAs for degradation. For example, UPF1 might be responsible for the decay of the SLBP protein, which is rapidly degraded by the proteosome at the end of S-phase [35] and is necessary for the shut off histone mRNA biosynthesis. [36] Given that UPF1 associates with SLBP to promote histone mRNA degradation, [37] a reasonable hypothesis is that UPF1 may also be responsible for promoting the decay of SLBP.
Conclusions and Outlook
UPF1 is a multifaceted molecule with diverse molecular and developmental roles. Loss of UPF1 in early development results in embryonic lethality and loss-of-function mutations in UPF1 acquired later in development result in disease. The discovery that human UPF1 is a E3 ligase that triggers protein decay raises the possibility that this new function is responsible for some of UPF1's many biological activities. Future studies will be necessary to assess this and define the extent to which UPF1 shapes the proteome. In the words of Benjamin Franklin, "Hide not your talents. They for use were made. What's a sundial in the shade?" Abbreviations NMD, nonsense-mediated RNA decay; PTC, premature termination codon; SLBP, stem-loop-binding protein; SMD, staufen (STAU)1-mediated.
